Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination among healthcare workers

Background A third dose of COVID-19 vaccination (COVID booster vaccination) has become established as an important measure to strengthen the immune response against SARS-CoV-2. In contrast, seasonal influenza vaccination has been an important infection prevention measure for years, especially among...

Full description

Saved in:
Bibliographic Details
Published in:medRxiv 2022-06
Main Authors: Wagenhäuser, Isabell, Reusch, Julia, Gabel, Alexander, Höhn, Anna, Lâm, Thiên-Trí, Almanzar, Giovanni, Prelog, Martina, Krone, Lukas B, Frey, Anna, Schubert-Unkmeir, Alexandra, Dölken, Lars, Frantz, Stefan, Kurzai, Oliver, Vogel, Ulrich, Petri, Nils, Krone, Manuel
Format: Article
Language:English
Subjects:
Clinical trials
Coronaviruses
COVID-19 vaccines
Enzyme-linked immunosorbent assay
Health care
Immune response (humoral)
Immunogenicity
Immunoglobulin G
Influenza
Medical personnel
Medical research
mRNA
Patients
Severe acute respiratory syndrome coronavirus 2
Side effects
Statistical analysis
Vaccines
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background A third dose of COVID-19 vaccination (COVID booster vaccination) has become established as an important measure to strengthen the immune response against SARS-CoV-2. In contrast, seasonal influenza vaccination has been an important infection prevention measure for years, especially among highly exposed healthcare workers (HCWs). Coadministration of vaccines against COVID-19 and seasonal influenza could be an efficient strategy to protect HCWs from two major viral respiratory infections. Yet, the immunogenicity and safety of coadministration remains to be evaluated. Methods This study examines the differences in Anti-SARS-CoV-2-Spike IgG antibody formation as well as side effects based on a digital questionnaire after a third COVID-19 vaccination with or without coadministration of a seasonal quadrivalent influenza vaccine (Influvac Tetra vaccine 2021/2022). 1,231 HCWs were recruited who received a mRNA-based booster COVID-19 vaccination (mRNA-1273 or BNT162b2mRNA) after basic immunisation with BNT162b2mRNA twice. Anti-SARS-CoV-2-Spike IgG levels were determined at least 14 days after vaccination by SERION ELISA agile SARS-CoV-2 IgG. Findings Anti-SARS-CoV-2-Spike IgG concentrations were by 25.4% lower in individuals with coadministration of the seasonal quadrivalent influenza vaccination than without (p
DOI:10.1101/2022.06.09.22276030